Skip to main content

Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies.

Publication ,  Journal Article
Hathaway, CA; Conejo-Garcia, JR; Fridley, BL; Rosner, B; Saeed-Vafa, D; Moran Segura, C; Nguyen, JV; Hecht, JL; Sasamoto, N; Terry, KL ...
Published in: Cancer Epidemiol Biomarkers Prev
June 1, 2023

BACKGROUND: Despite the immunogenic nature of many ovarian tumors, treatment with immune checkpoint therapies has not led to substantial improvements in ovarian cancer survival. To advance population-level research on the ovarian tumor immune microenvironment, it is critical to understand methodologic issues related to measurement of immune cells on tissue microarrays (TMA) using multiplex immunofluorescence (mIF) assays. METHODS: In two prospective cohorts, we collected formalin-fixed, paraffin-embedded ovarian tumors from 486 cases and created seven TMAs. We measured T cells, including several sub-populations, and immune checkpoint markers on the TMAs using two mIF panels. We used Spearman correlations, Fisher exact tests, and multivariable-adjusted beta-binomial models to evaluate factors related to immune cell measurements in TMA tumor cores. RESULTS: Between-core correlations of intratumoral immune markers ranged from 0.52 to 0.72, with more common markers (e.g., CD3+, CD3+CD8+) having higher correlations. Correlations of immune cell markers between the whole core, tumor area, and stromal area were high (range 0.69-0.97). In multivariable-adjusted models, odds of T-cell positivity were lower in clear cell and mucinous versus type II tumors (ORs, 0.13-0.48) and, for several sub-populations, were lower in older tissue (sample age > 30 versus ≤ 10 years; OR, 0.11-0.32). CONCLUSIONS: Overall, high correlations between cores for immune markers measured via mIF support the use of TMAs in studying ovarian tumor immune infiltration, although very old samples may have reduced antigenicity. IMPACT: Future epidemiologic studies should evaluate differences in the tumor immune response by histotype and identify modifiable factors that may alter the tumor immune microenvironment.

Duke Scholars

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

June 1, 2023

Volume

32

Issue

6

Start / End Page

848 / 853

Location

United States

Related Subject Headings

  • Tumor Microenvironment
  • Prospective Studies
  • Ovarian Neoplasms
  • Immunohistochemistry
  • Humans
  • Female
  • Epidemiology
  • Epidemiologic Studies
  • Child
  • Biomarkers, Tumor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hathaway, C. A., Conejo-Garcia, J. R., Fridley, B. L., Rosner, B., Saeed-Vafa, D., Moran Segura, C., … Townsend, M. K. (2023). Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies. Cancer Epidemiol Biomarkers Prev, 32(6), 848–853. https://doi.org/10.1158/1055-9965.EPI-22-1285
Hathaway, Cassandra A., Jose R. Conejo-Garcia, Brooke L. Fridley, Bernard Rosner, Daryoush Saeed-Vafa, Carlos Moran Segura, Jonathan V. Nguyen, et al. “Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies.Cancer Epidemiol Biomarkers Prev 32, no. 6 (June 1, 2023): 848–53. https://doi.org/10.1158/1055-9965.EPI-22-1285.
Hathaway CA, Conejo-Garcia JR, Fridley BL, Rosner B, Saeed-Vafa D, Moran Segura C, et al. Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies. Cancer Epidemiol Biomarkers Prev. 2023 Jun 1;32(6):848–53.
Hathaway, Cassandra A., et al. “Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies.Cancer Epidemiol Biomarkers Prev, vol. 32, no. 6, June 2023, pp. 848–53. Pubmed, doi:10.1158/1055-9965.EPI-22-1285.
Hathaway CA, Conejo-Garcia JR, Fridley BL, Rosner B, Saeed-Vafa D, Moran Segura C, Nguyen JV, Hecht JL, Sasamoto N, Terry KL, Tworoger SS, Townsend MK. Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies. Cancer Epidemiol Biomarkers Prev. 2023 Jun 1;32(6):848–853.

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

June 1, 2023

Volume

32

Issue

6

Start / End Page

848 / 853

Location

United States

Related Subject Headings

  • Tumor Microenvironment
  • Prospective Studies
  • Ovarian Neoplasms
  • Immunohistochemistry
  • Humans
  • Female
  • Epidemiology
  • Epidemiologic Studies
  • Child
  • Biomarkers, Tumor